New warning information for ADHD drugs

Share this article:
Two attention deficit hyperactivity disorder (ADHD) drugs must include new information about heart risks and psychotic behavior, the FDA said yesterday. GlaxoSmithKline’s Dexedrine and Novartis’ Ritalin will include a warning about the possible risk of sudden death and serious heart problems, Reuters reported. At press time it was unclear whether ADHD drugs from Johnson & Johnson's (Concerta) and Eli Lilly (Strattera) were also ordered to carry the warnings. The FDA's decision comes months after two separate panels of outside experts offered conflicting opinions on whether the risks warranted black box warnings.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.